HC Wainwright Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price

Vigil Neuroscience (NASDAQ:VIGL) had its price target dropped by HC Wainwright from $17.00 to $14.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other equities analysts have also commented on VIGL. JMP Securities reaffirmed a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. William Blair initiated coverage on shares of Vigil Neuroscience in a research note on Wednesday, December 4th. They set an “outperform” rating on the stock. Finally, Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $19.00.

Vigil Neuroscience Trading Down 10.2 %

Shares of VIGL stock opened at $2.11 on Friday. Vigil Neuroscience has a 12-month low of $1.49 and a 12-month high of $6.06. The business’s fifty day simple moving average is $2.34 and its 200-day simple moving average is $2.80. The company has a market cap of $86.25 million, a PE ratio of -1.02 and a beta of 1.82.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.08). On average, equities analysts forecast that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Institutional Investors Weigh In On Vigil Neuroscience

Large investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC lifted its stake in Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock valued at $41,000 after acquiring an additional 8,358 shares during the period. Northern Trust Corp raised its holdings in shares of Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock worth $110,000 after purchasing an additional 14,572 shares during the last quarter. Barclays PLC lifted its position in Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company’s stock valued at $109,000 after purchasing an additional 19,436 shares during the period. Two Sigma Investments LP boosted its holdings in Vigil Neuroscience by 44.0% in the fourth quarter. Two Sigma Investments LP now owns 136,920 shares of the company’s stock valued at $233,000 after purchasing an additional 41,836 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Vigil Neuroscience during the 4th quarter worth about $83,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.